New Year New You Use Code “NEWYEAR50” for $50 Off

The Potential of Semaglutide In Weight Loss: Navigating Pregnancy Considerations

Published January 23, 2024

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained attention for its effectiveness in weight loss. This blog post explores the use of semaglutide in weight management and addresses its implications during pregnancy. While semaglutide shows promise as a powerful tool in the battle against obesity, it is crucial to understand its safety profile, especially for individuals considering or currently experiencing pregnancy.

Safety and Efficacy:

As with any medication, it is essential to consider both the benefits and potential risks associated with semaglutide. Common side effects include nausea, vomiting, and diarrhea, which are usually mild and transient. However, serious side effects such as pancreatitis and medullary thyroid cancer have been reported, albeit rarely.

Pregnancy Considerations:

Pregnancy introduces a unique set of considerations when it comes to medication use. The safety of semaglutide during pregnancy is not well-established, Therefore, we must carefully weigh the potential risks and benefits. Risks include fetal malformations and death.

While animal studies have not shown teratogenic effects, limited data exist on semaglutide use in pregnant humans. It is crucial for individuals planning pregnancy or those who are already pregnant to consult with their healthcare providers. In some cases, alternative weight management strategies may be recommended to ensure the well-being of both the mother and the developing fetus. At C & J Weight Loss, we recommend the use of contraception during Semaglutide use and stopping Semaglutide 3 months before planning to become pregnant.

Patient-Centered Decision-Making:

Shared decision-making between healthcare providers and patients is vital when considering semaglutide for weight loss, especially in the context of pregnancy. Open communication about individual health goals, lifestyle factors, and potential risks is essential to make informed choices.
Semaglutide represents a significant advancement in the field of weight management, offering a promising solution for those struggling with obesity. However, its use during pregnancy raises important questions about safety that require careful consideration.

As research continues to evolve, healthcare providers and patients must collaborate to make well-informed decisions regarding semaglutide use. It is essential to prioritize the health and safety of both the individual and, when applicable, the developing fetus.

Sources:

FDA Approves Once-Weekly Semaglutide for Adults with Overweight or Obesity. (2021). [FDA News Release] Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., … & Investigators, S. T. E. P. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414-1425. Semaglutide Pregnancy and Breastfeeding Warnings. (n.d.). [Drugs.com] Aroda, V. R., Saugstrup, T., & Buse, J. B. (2021). Dose-dependent effects of once-weekly semaglutide on glycemic control and weight in patients with type 2 diabetes. Diabetes Care, 44(2), 678-684.